1 / 9

Thanks for your attention prepared by : sujood dabeek

Drug Name: Afinitor ( everolimus ) Company: Novartis Approval Status: Approved March 2009 Treatment Area: renal cell carcinoma.

zed
Download Presentation

Thanks for your attention prepared by : sujood dabeek

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Drug Name: Afinitor (everolimus)Company: NovartisApproval Status: Approved March 2009Treatment Area: renal cell carcinoma

  2. M.O.A:Afinitor is an inhibitor of mTOR (mammalian target of rapamycin), a serine-threoninekinase. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellular protein, FKBP-12, resulting in an inhibitory complex formation and inhibition of mTORkinase activity. Inhibition of mTOR by everolimus has been shown to reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.

  3. The use of mTOR inhibitors is considered a promising therapeutic approach in renal cell carcinoma.The inhibition of mTOR may:1.Inhibit abnormal cell proliferation, tumor angiogenesis and abnormal cell metabolism2.Enhance the efficacy of other cancer treatments .

  4. mTOR: A central regulator of cell proliferation, angiogenesis and cell metabolismmTOR is an important therapeutic target because:It is a key intracellular point of convergence for a number of signaling pathways that are abnormally activated in many types of cancer.It appears to be a stable target that does not mutate

  5. Afinitor is specifically indicated for the treatment of advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib. The proven therapy in advanced renal cell carcinoma after VEGF failure.

  6. Dosing & administration recommendations:The recommended once-daily dose of AFINITOR is 10 mgAFINITOR should be taken orally, once daily at the same time, consistently either with or without food and with a full glass of waterThe tablets should not be chewed or crushedThe dosage may be reduced to 5 mg daily when appropriateIf a dose is missed, the patient should not take an additional dose, but take the usual prescribed next doseAFINITOR is available as 5 mg and 10 mg tablets with no score.

  7. Side Effects:Adverse events associated with the use of Afinitor may include, but are not limited to, the following: StomatitisInfections and infestations Asthenia Fatigue Diarrhea Cough Rash Nausea Anorexia

  8. Thanks for your attentionprepared by :sujooddabeek

More Related